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The current evidence suggests that beneficial effects of mesenchymal stem cells (MSCs)
toward myocardial repair are largely due to paracrine actions of several factors. Although
Monocyte chemoattractant protein-induced protein 1 (MCPIP1) is involved in the regulation
of inflammatory response, apoptosis and angiogenesis, whether MCPIP1 plays any role in
stem cell-induced cardiac repair has never been examined. By employing retroviral (RV)-
transduced overexpression of MCPIP1, we investigated the impact of MCPIP1 on viability,
apoptosis, proliferation, metabolic activity, proteome, secretome and differentiation capacity
of murine bone marrow (BM) - derived MSCs. MCPIP1 overexpression enhanced angio-
genic and cardiac differentiation of MSCs compared with controls as indicated by elevated
expression of genes accompanying angiogenesis and cardiomyogenesis in vitro. The
proangiogenic activity of MCPIP1-overexpressing MSCs (MCPIP1-MSCs) was also con-
firmed by increased capillary-like structure formation under several culture conditions. This
increase in differentiation capacity was associated with decreased proliferation of MCPIP1-
MSCs when compared with controls. MCPIP1-MSCs also expressed increased levels of
proteins involved in angiogenesis, autophagy, and induction of differentiation, but not
adverse inflammatory agents. We conclude that MCPIP1 enhances endothelial and cardiac
differentiation of MSCs. Thus, modulating MCPIP1 expression may be a novel approach
useful for enhancing the immune-regulatory, anti-apoptotic, anti-inflammatory and regener-
ative capacity of BM-derived MSCs for myocardial repair and regeneration of ischemic
tissues.
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Introduction
Bone marrow (BM)-derived mesenchymal stem cells (MSCs) have been used extensively for
tissue regeneration due to their broad differentiation potential, low immunogenicity and innate
anti-inflammatory properties [1–3]. It has also been reported that a fraction of MSCs are able
to differentiate into cardiomyocytes and endothelial cells following stimulation in vitro or in
vivo [4–9]. Several recent studies indicate that therapy with BM-derived MSCs improves left
ventricular (LV) function and myocardial perfusion after myocardial infarction (MI) [1, 10–
12]. However, the benefits of MSC therapy for cardiac repair in vivo has been variable [1, 10].
Therefore, several approaches have been employed to enhance the capacity of MSCs for
ischemic tissue repair. These include overexpression of multiple exogenous factors, including
anti-apoptotic and pro-surviving proteins (e.g. Hsp20, Hsp27, survivin) [13–15] as well as
growth factors with pleiotropic effects, including proangiogenic activities (e.g. vascular endo-
thelial growth factor (VEGF), hepatocyte growth factor (HGF), angiopoietin-1, glycogen
synthase kinase-3β (GSK-3β), sonic hedgehog (Shh)) [16–20]. Although such strategies have
been attempted for many years, there is still no optimized set of factors or individual molecule
that may definitively augment the reparative properties of MSCs and enhance cardiac repair.
Monocyte Chemoattractant Protein-1–Induced Protein 1 (MCPIP1; Zc3h12a) has been iden-
tified in human macrophages following stimulation with interleukin 1β (IL-1β) [21]. Although
the highest level of MCPIP1 has been found in leukocytes, it may also be expressed in other cell
types [21]. MCPIP1 has been shown to be induced by several proinflammatory agents and cyto-
kines, and may act as a macrophage activator and negative regulator of oxidative stress and
inflammatory gene expression [22]. Moreover, overexpression of MCPIP1 in these cells signifi-
cantly decreased promoter activity of tumor necrosis factor α (TNF-α) and inducible nitric-oxide
synthase (iNOS) in a dose-dependent manner, indicating anti-inflammatory properties [22].
Interestingly, it has recently been shown that MCPIP-1 exhibited RNAse activity due to the pres-
ence of a PilT N-terminus (PIN) domain and may play a regulatory (including anti-inflamma-
tory) role via mRNA and pre-miRNA decay in different cell types, including non-hematopoietic
cells [21, 23, 24]. Importantly, Niu and colleagues have reported that MCPIP1 may be involved in
enhancing angiogenic activity and secretion of several proangiogenic factors in human umbilical
vein endothelial cells (HUVECs) [25]. Moreover, the specific knockdown of MCPIP1 in these
cells resulted in suppression of VEGF and hypoxia-inducible factor-1α (HIF-1α), which are
important agents involved in proangiogenic and antioxidative cell responses [25]. Notably, stud-
ies employing transgenic mice with myocardial MCPIP1 expression (under an α-MHC pro-
moter) have reported extensive attenuation of inflammatory response-related cardiac dysfunction
[26]. Data from several laboratories strongly indicate that MCPIP1 may reside in both cyto-
plasmic as well as nuclear compartments with distinct roles in different cell types [21, 23, 27].
Although the impact of MCPIP1 on angiogenic potential, survival and inflammatory
response was studied in several mature cell types, the role of MCPIP1 in stem cells, such as
MSCs has never been investigated. Thus, in this study we evaluated the impact of MCPIP1 on
several functions of MSCs, including cell viability and apoptosis, proliferation, metabolic activ-




Four-to-six-week-old C57Bl/6 mice were used for experiments. All procedures were performed
in accordance with the approval of the Ethical Committee on Animal Testing at the
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Jagiellonian University (JU) in Krakow (approval number: 31/2012). C57Bl/6 mice were sup-
plied for experiments by Charles River (Wilmington MA, USA) and were subsequently held
for 7 day quarantine, prior to their experimental use, in Animal Facility of Department of Bio-
physics at the Faculty of Biochemistry, Biophysics and Biotechnology JU in Krakow. Mice were
handled accordingly to standard animal procedures complied in controlled animal facilities.
Up to 5 mice of the same gander were kept per one cage and were constantly controlled for
health conditions, supplied with water and dry fodder containing balanced nutrition and were
handled accordingly to the standard regulations. Animals were sacrificed by intraperitoneal
injection of lethal dose of pentobarbital (Morbital; Biowet, Pulawy, Poland; 100mg/kg b.w.)
representing acceptable method for mice euthanasia and accordingly to the ethical approval
listed above. Tibias and femurs were harvested immediately following the animal euthanasia.
Isolation and culture of MSCs
Bone marrow cells were harvested by flushing cavities of tibia and femur bones with DMEM/
F12 medium (Sigma-Aldrich). Cells were centrifuged, re-suspended in complete medium
(DMEM/F12 with 10% FBS, Sigma-Aldrich; and penicillin/ streptomycin, Gibco, Life Technol-
ogies) and seeded into a Primaria culture flask (BD Falcon) at a density of 25x106 nucleated
cells/ 75cm2. Flushed bones were additionally fragmented and enzymatically digested with col-
lagenases type I and II (1 mg/ml; Sigma Aldrich) for 1.5h at 37°C. Released cells were washed
and added equally to flasks containing flushed BM cells. Cells were cultured in standard condi-
tions for 72h and non-adherent cells were removed. Cells were passaged with 0.25% trypsin/
EDTA (Gibco, Life Technologies) when confluence of cells reached close to 90%.
Retrovirus generation
Retroviral vectors containing the following plasmids were prepared in our laboratory and used
in the study: pMX-MCPIP1 coding for MCPIP1, pMX-GFP (control plasmid containing insert
with enhanced green fluorescence protein (GFP)), and pMX-Puro (empty plasmid, devoid of
any insert). Retrovirus packaging was performed in a modified HEK293 (Phoenix Amphotro-
pic) as described earlier [28].
Retroviral transduction
To obtain MCPIP1 overexpressing MSCs, retrovirus-mediated gene transfer based on
pMX-Puro system was performed [29]. MSCs on passage 3 to 4 were transduced with vectors:
pMX-MCPIP1, pMX-GFP or pMX-Puro. Each vector was added to 0.5x106 MSCs in the pres-
ence of 4 μg/ml polybrene (Merck Millipore) in complete growth medium (MOI = 7). The
medium was changed after 24h. In order to increase the population of MCPIP1-overexpressing
cells, transduction was repeated after 48h.
Viability, proliferation and metabolic activity assessment
The viability and metabolic status of MSCs were measured by MTT assay and ATP concentra-
tion, respectively. Tests were performed at 48 and 72h after second transduction.
MTT assay
Cells were seeded on transparent 96-well plates (BD Falcon) to reach 90% of confluence. Then
MTT (500 ng/ml; Sigma-Aldrich) was added for 4h. The medium was removed and acidic iso-
propanol (40 mMHCl; POCh) was added for 30 min. Absorbance was measured with an
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Infinite 200 microplate reader (Tecan Group Ltd.) at a wavelength of 570 nm with background
subtraction at 650 nm.
ATP concentration measurement
MSCs were seeded on 96-well white plates to obtain 90% of confluence in each time point and
the ATP Lite Luminescence assay kit was performed according to manufacturer’s instructions
(Perkin Elmer). Luminescence was measured using the SpectraFluor Plus (Tecan Group Ltd)
microplate reader.
Proliferation ratio assessment
The relative proliferation ratio of MSCs was evaluated at 72h after the second transduction.
MSCs were counted with the Countess II Automated Cell Counter (Life technologies).
Western blotting
Expression of MCPIP1 at the protein level was detected by western blotting [30]. Briefly,
MCPIP1 was assessed using primary rabbit anti-MCPIP1 antibody [21]. As a loading control,
primary mouse anti-actin antibody (Sigma-Aldrich) was used. Detailed procedure is included
in S1 Appendix (Extended Materials and Methods).
Antigenic phenotyping by flow cytometry
The phenotype of MSCs was evaluated at 72h after the second transduction. MSCs were immu-
nolabelled with the following monoclonal antibodies: anti-CD45 (APC-Cy7 or FITC, clone:
30-F11, BD Bioscence), anti-Sca-1 (PE, clone: E13-161.7, BD Bioscence), anti-CD105 (PE/Cy7,
clone: MJ7/18, BioLegend), and anti-CD90.2 (APC, clone: 30-H12, BioLegend). Staining was
performed according to manufacturer’s protocols for 30 min at 4°C. Cells were analyzed using
LSR II flow cytometer and FACS Diva software (Becton Dickinson).
Necrosis and apoptosis detection
Assessment of necrosis and apoptosis was done with Annexin V Apoptosis Detection Kit (BD
Biosciences) and by Vybrant FAM Caspase-3 and 7- Assay Kit (Life Technologies) with flow
cytometry. Staining was performed according to manufacturer’s protocols and analyzed using
using LSR II flow cytometer and FACS Diva software (Becton Dickinson).
Global proteomic analysis—sample processing
MSCs (1.7 x 106) from all groups were lysed in 4% SDS and 0.1 M DTT in Tris-HCl (BioShop,
pH 7.6) and sonicated for 10 min. The samples were further incubated at 95°C for 5 min and
centrifuged at 30,000g for 30 min at 20°C. Then, the proteins were digested using the filter
aided sample preparation (FASP) technique [31] (detailed procedures including liquid chro-
matography and tandem mass spectrometry as well as analysis of proteomic data are included
in S1 Appendix (Extended Materials and Methods).
Capillary-like tube formation assay
Twenty four-well plates were coated with Matrigel Matrix Grow Factor Reduced (BD Pharmin-
gen) (100μl/well) and incubated at 37°C for 30 min. MCPIP1-expressing MSCs and control
MSCs were seeded at a density of 1x105 cells/well in the EGM-2MVmedium (Clonetics,
Lonza). HUVECs were used as a positive control, while freshly isolated total nucleated cells
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(TNCs) from murine BM were utilized as a negative control. Cells were incubated for 12 or
18h at 37°C. Tube formation was investigated every 2h and images were collected with an
Olympus IMT-2 microscope equipped with a CCD camera. The results were computed as
absolute number of capillary-like structures and branches per field formed by cultured cell
groups at different time points along the assay.
Cardiomyogenic and angiogenic differentiation
Cardiomyogenic differentiation. MSCs were cultured on a dish coated with 50 μg/ml col-
lagen type I (Sigma-Aldrich) in DMEM/F12 with 2% FBS (Sigma-Aldrich) and 10ng/ml bFGF,
10ng/ml VEGF and 10 ng/ml TGFβ1 [32] (all growth factors from R&D Systems). Cells were
examined for cardiac differentiation after 5 and 10 days of culture.
Endothelial differentiation. MSCs were cultured on a dish coated with both fibronectin
(50 μg/ml, Corning) and gelatin (0.1%, Sigma-Aldrich) in EGM-2MV endothelial medium
(Lonza). Cells were examined for angiogenic differentiation after 5 and 10 days of culture.
Gene expression analysis by quantitative real-time RT-PCR
Total RNA was isolated with GeneMATRIX Universal RNA Purification Kit (EURx) and
200ng of total RNA was used for reverse transcription with TaqMan Reverse Transcription
Reagents (Life Technologies) performed according to the manufacturer’s protocol. Expression
of genes related to pluripotency state (Oct-3/4A, Sox2, Klf4, c-Myc), cardiac (Gata-4, Nkx2.5,
Myl2, Myh6) and endothelial (Gata-2, Tie-2, VE-cadherin, vonWillebrand factor (vWF)) dif-
ferentiation were examined by real-time PCR using an ABI PRISM 7000 system (Applied Bio-
systems). β2-microglobulin was used as a control housekeeping gene.
Real-time PCR was performed using Sybr Green qPCRMaster Mix (EURx), cDNA template
(10ng), forward and reverse primer (1μM; Genomed). The sequences of primers are included
in S1 Appendix (Extended Materials and Methods). Relative quantification of gene expression
was calculated using the comparative Ct method. The relative quantitative value of the target
normalized to an endogenous control (β2-microglobulin gene) and relative to a calibrator was
expressed as 2-ΔΔCt (i.e.-fold difference).
Immunocytochemistry
Immunocytochemistry staining was performed to evaluate: i) Gata-4 and troponin T-C; and ii)
Gata-2 and VE-cadherin expression in MSC-derived cardiac and endothelial cells, respectively.
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, washed,
and stained with primary anti-Gata-4 and anti-troponin T-C antibodies or with anti-Gata-2
and anti-VE-cadherin antibodies followed by secondary antibodies and DAPI. Cells were ana-
lyzed with a Leica DM IRE2 (Ver. 4000) fluorescent microscope. A detailed description of the
staining procedure and used antibodies are included in S1 Appendix (Extended Materials and
Methods).
Secretome analysis
Western blotting (semi-quantitative). MCPIP1-expressing MSCs and control cells at 72h
following the second transduction were cultured in EGM-2MVmedium for 10 days and subse-
quently were washed twice with DMEM/F12 and further cultured in DMEM/F12 with 0.5%
BSA (Sigma-Aldrich) for 24h. Cell culture supernatants were collected and frozen at -80°C
until analysis. Analysis of expression of 53 angiogenesis-related proteins was carried out using
the Proteome Profiler Mouse Angiogenesis Array Kit (R&D Systems) according to the
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manufacturer’s protocol. The average signals (pixel density) computed from duplicate spots
representing each angiogenesis-related protein were determined by Quantity One software
(BioRad). An average background signal was subtracted from each spot during the analysis.
Multiplex analysis (quantitative). In addition, cell culture supernatants were evaluated
for the presence of selected angiogenesis- related factors with a Luminex-based platform.
Quantitative analysis of concentrations of endoglin, endothelin, VEGF-α, HGF, SDF-1, MCP-1
and IL-1β was performed using the Milliplex MAP Kit (Mouse Angiogenesis/Growth Factor
Magnetic Bead Panel; EMDMillipore) according to the manufacturer’s protocol. Protein con-
centrations were read on a Luminex platform (Austin). Median Fluorescent Intensity (MFI)
for each protein was analyzed using 5-parameter logistic or spline curve-fitting method for cal-
culating concentrations in tested samples by in Luminex IS 2.3 Software (Austin).
Statistical analysis
All experiments were carried out in triplicates (except global proteome analysis which was
repeated twice). In every repetition of the experiment was used primary culture of MSCs at pas-
sage 3–4. Results are presented as mean values ± standard deviations (SD). Paired Student’s t
tests were used to compare MCPIP1-overexpressing MSCs and Puro-treated cells. Untreated
Control cells were used in all experiments as a negative control. A P value<0.05 was consid-
ered as statistically significant. All statistical analyses were performed using the Origin (ver.
9.1) statistical software (Microcal Software).
Results
MCPIP1 is efficiently overexpressed in primary MSCs following retroviral
transduction
To evaluate the impact of MCPIP1 on functions of BM-derived MSCs, cells were transduced
with retroviral vectors carrying the sequence coding MCPIP1 (MCPIP1-MSCs). Empty vector-
treated (Puro) or untreated (Control) MSCs were used as controls. In order to confirm expres-
sion of MCPIP1 at the mRNA level, total RNA was isolated fromMSCs at 48 and 72 hours
after transduction. The relative level of expression of mRNA for MCPIP1 was computed in
comparison with Puro-treated cells (set as 1) (S1C Fig). The expression of transcript in
MCPIP1-MSCs was higher in comparison with control cells at each time point. However, the
highest concentration of mRNA for MCPIP1 was observed at 72h post transduction in
MCPIP1-MSCs (S1C Fig), while the transcript was hardly detectable in untreated Control cells.
The expression was also confirmed on protein level (S1D Fig).
To investigate the potential impact of MCPIP1 on MSC viability and metabolic activity, sev-
eral functional tests were done at the indicated time points post transduction. Thus, MTT
assay was used to measure cytotoxic effects of MCPIP1 at 48 and 72h following viral transduc-
tion. Relative viability was computed when compared with Puro-treated cells (shown as 1). We
did not observe any notable impairment of cell viability after transduction with retroviral vec-
tors at each time point (S1E Fig). The effect of MCPIP1 on MSC metabolic activity was evalu-
ated by the ATP measuring assay. Relative metabolic activity was also computed in
comparison to Puro-treated cells (set as 1). We did not find a significant impact of MCPIP1
protein on metabolic activity of MSCs at any time-point (S1F Fig).
The transduction efficiency was evaluated following MSC treatment with a retroviral vector
carrying GFP for 72h by applying both fluorescent microscopy and flow cytometry (S1A and
S1B Fig). A total of 60.0 ± 16.5% of transduced adherent fraction of cultured BM cells expressed
GFP, corresponding to transduction efficiency within the entire fraction of cells (S1B Fig).
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Thus, because of the highest expression of MCPIP1 observed at 72h post transduction that was
not accompanied by significant impairment in viability or metabolic activity of MCPIP1- overex-
pressing MSCs, the cells at this time-point after transduction were subsequently used for further
experiments examining the impact of MCPIP1 on several MSC functions including SC-related
gene expression as well as angiogenic and cardiomyogenic differentiation potential in vitro.
MCPIP1 does not affect antigenic phenotype and viability but decreases
MSC proliferation
To evaluate the impact of MCPIP1 on MSC viability and apoptosis activation, several assays
were done at 72h post transduction. Apoptosis and necrosis were examined by phosphatydylo-
serine detection and 7-aminoactinomycin D staining as well as by evaluation of caspase-3 and
-7 activation. No major impact of MCPIP1 on MSC viability was noted. A small fraction of
cells (less than 5%) undergoing cell death was detected within in all groups of MSCs (Fig 1A).
We also evaluated the impact of MCPIP1 on proliferation of MSCs at 72h after transduc-
tion. Interestingly, we found that MCPIP1 overexpression was associated with a significant
decrease in MSC proliferation rate when compared with both control groups (Fig 1B). How-
ever, the proliferative activity of MSCs overexpressing MCPIP1 was still sustained at a rela-
tively high level (80.19% ± 7.34 when compared with Puro-treated cells). Importantly, we did
not observe any major differences in morphology between MCPIP1-overexpressing MSCs and
control cells (Fig 1B).
To investigate the potential influence of MCPIP1 overexpression on expression of classical
MSC markers and the content of major antigenically- defined MSC subpopulations, we evalu-
ated the multiantigenic profile of transduced cells by immunostaining against CD45, CD90.2,
CD105 and Sca-1 antigens followed by flow cytometric analysis (Fig 1C). We found that similar
to control cells, MCPIP1-overexpressing MSCs consist of three main subpopulations including
CD90+/CD105-, CD105+/Sca-1+ and CD90+/Sca-1+ that represent 82.7±5.2%; 88.1±4.4% and
92.4±2.0% of CD45-negative MSC population, respectively (Fig 1C). Furthermore, no major
effect on expression of MSC-related surface antigens was observed in cells with MCPIP1 over-
expression. Thus, the content of main subsets of MSCs was comparable between MCPIP1-o-
verexpressing cells and both control groups (Fig 1C).
MCPIP1 decreases expression of pluripotency-associated genes and
enhances differentiation capacity of MSCs
The expression of pluripotency markers such as Oct-3/4A, Klf-4, c-Myc and Sox2 was evalu-
ated at the mRNA level by real-time RT-PCR (Fig 2A) to assess whether MCPIP1 may be
involved in regulation of stem cell-related genes. The results showed that MCPIP1 overexpres-
sion was associated with a decreased level of Oct-4 and Klf-4 (transcription factors maintaining
stemness) in comparison with Puro-treated and untreated Control MSCs (Fig 2A).
Importantly, the Matrigel assay showed that the decrease in SC- related gene expression was
accompanied by enhanced angiogenic differentiation capacity of MSCs expressing MCPIP1
when compared with control groups of MSCs (Fig 2C and 2D). In quantitative analysis (S1B
Fig), we observed faster and greater formation of capillary-like structures by MSCs expressing
MCPIP1 when compared with control cells (Fig 2C and 2D, S1 Table). The results suggest a
role for MCPIP1 in enforcing the differentiation capacity of MSCs.
Interestingly, the proteomic data may also suggest that MCPIP1 expression favors decreased
proliferative status of MSCs along with promoting their differentiation ability. Mass spectros-
copy was used to evaluate the global proteome of all examined groups of MSCs. In each ana-
lyzed sample were detected more than 2600 proteins (Fig 2B). We found several proteins
MCPIP1 Enhances Differentiation Potential of MSCs
PLOSONE | DOI:10.1371/journal.pone.0133746 July 27, 2015 7 / 25
uniquely expressed or with elevated concentration in MCPIP1- expressing MSCs when com-
pared with Puro-treated cells, including proteins involved in cell proliferation, differentiation,
Wnt/β-catenin signaling as well as regulating processes of apoptosis and autophagy (Table 1).
Interestingly, several proteins negatively regulating cell proliferation were present in this group
including testin and protein phosphatase 1G implicated in negative regulation of cell prolifera-
tion and cell cycle arrest, respectively (Table 1). Moreover, we identified several proteins not
present in MCPIP1-overexpressing MSCs when compared with Puro cells, including proteins
negatively regulating Notch signaling as well as involved in apoptosis and intracellular reorga-
nization (Table 2). Thus, the proteomic profile of MCPIP1-overexpressing MSCs corresponds
to their lower proliferative activity and enhanced differentiation capacity.
Fig 1. Impact of MCPIP1 expression on selected functions of MSCs at 72h post transduction. (A) Viability and apoptosis induction by flow cytometry
assays. Table represents percent content of cells undergoing necrosis, early apoptosis, late apoptosis and exhibiting caspase 3 and 7 activation among
MCPIP1- overexpressing MSCs, empty vectors (Puro)- treated and untreated (Control) MSCs. (B) Proliferation by Countess II Automated Cell Counter (Life
Technologies) (left). The graph shows the relative level of proliferation of MCPIP1-overexpressing MSCs (black bar) when compared with Puro-treated cells
(hatched bar; recalculated as 1) and untreated Control MSCs (white bar). Morphology of MCPIP1- overexpressing MSCs, empty vectors (Puro)- treated and
untreated (Control) MSCs (right). Scale bars: 100 μm. (C) Antigenic profile of MSCs by flow cytometry. Expression of CD90, CD105 and Sca-1 antigens on
MCPIP1-overexpressing MSCs and control cells (Control and Puro) is shown on representative dot-plots. Analyzes were performed on CD45- subsets
indicating MSCs using the LSR II flow cytometer (Becton Dickinson). Right graph shows quantitative data representing percent content of each
subpopulation of antigenically-defined MSCs among three experimental groups. All results are presented as mean ± SD. Statistically significant differences
(P<0.05) are shown when compared with Puro (*) and Control (#). Analysis based on three independent experiments. Control—untreated MSCs; Puro—
empty vector-treated MSCs; MCPIP1- MSCs overexpressing MCPIP1.
doi:10.1371/journal.pone.0133746.g001
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Fig 2. Stem cell-related genes and differentiation capacity of MSCs at 72h post transduction. (A)Quantitative analysis of mRNA expression for
pluripotency related genes by real-time RT-PCR. The graph shows expression of Oct-4, Klf-4, Sox2 and c-Myc in MCPIP1-overexpressing MSCs and control
cells (Puro, Control). Fold change in mRNA concentration was computed using the ddCt method when compared with Puro-treated cells (shown as 1). (B)
Global proteomic analysis of MSCs at 72h post transduction by mass spectroscopy. Upper panel- Average number of proteins identified in three MSC
groups: MCPIP1-overexpressing MSCs, empty vector (Puro)-treated MSCs and untreated (Control) MSCs. Middle panel- Scheme representing total number
of common proteins identified in pairs: MCPIP1-overexpressing MSCs vs. Control and MCPIP1-overexpressing MSCs vs. empty vector (Puro)- treated
MSCs; and number of common proteins that occur in all analyzed samples. Lower panel- Scheme showing number of proteins identified exclusively in each
experimental group as well as common proteins for all compared groups with dNAFs fold change in expression higher than 2.0. (C) The angiogenic potential
of MSCs determined by capillary-like tube formation assay. Photos show representative images of capillary- like structures formed on matrigel by MCPIP1-
overexpressing MSCs as well as Puro- treated and untreated Control MSCs. Scale bars: 100 μm. (D)Quantitative analysis of angiogenic potential of MSCs
overexpressing MCPIP1 when compared with control cells. Graphs represent number of branches at 2, 4, 6, 8 and 10h of capillary formation assay on
matrigel. Six randomly selected images of high-power fields for every experimental timepoint were included in quantitative analysis. HUVEC cells were used
as positive control, while freshly isolated BM cells represent the negative control. Numbers of branches formed by each cell fraction were computed based on
microscopic images as shown in S2B Fig, and the detailed results (Mean number ± SD) are included in S1 Table. All results are presented as mean ± SD.
Statistically significant differences (P<0.05) are shown when compared with Puro (*) and Control (#). Analysis based on three independent experiments.
Control—untreated MSCs; Puro—empty vector-treated MSCs; MCPIP1- MSCs overexpressing MCPIP1.
doi:10.1371/journal.pone.0133746.g002
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Table 1. Proteins unique or greatly expressed in MCPIP1- expressing MSCs when compared with Puro-treated MSCs.





Selected function [Based on UniProtKB]
Q5D1E8 Ribonuclease ZC3H12A ND Pro-inflammatory cytokines mRNA decay; angiogenesis
Q9CQB5 CDGSH iron-sulfur domain-containing protein 2 ND Autophagy regulation
P62257 Ubiquitin-conjugating enzyme E2 H ND Protein ubiquitination
Q6PFQ7 Ras GTPase-activating protein 4 ND Ras protein signal transduction regulation
P70444 BH3-interacting domain death agonist ND Caspases and apoptosis induction
Q8K3C3 Protein LZIC ND Wnt/ β-catenin signaling
Q3UL36 Arginine and glutamate-rich protein 1 ND ER-mediated transcription; required for cell growth
Quantitatively more in MCPIP1-overexpressing MSCs when compared with Puro
O35509 Ras-related protein Rab-11B 6.71 Key regulators of intracellular membrane trafficking
P47226 Testin 5.43 Negative regulation of cell proliferation
P70362 Ubiquitin fusion degradation protein 1 homolog 4.10 Proteasome-mediated ubiquitin-dependent protein catabolic
process
Q61074 Protein phosphatase 1G 3.63 Cell cycle arrest
Q9ERN0 Secretory carrier-associated membrane protein 2 3.56 Recycling carrier to the cell surface
Q9Z2M7 Phosphomannomutase 2 3.55 Fructose and mannose metabolism
P48771 Cytochrome c oxidase subunit 7A2, mitochondrial 3.39 Respiratory electron transport chain
Q8CI08 SLAIN motif-containing protein 2 3.29 Microtubule organization
P11730 Calcium/calmodulin-dependent protein kinase type II
subunit gamma
3.02 Sarcoplasmic reticulum Ca2+ transport in skeletal muscle
Q9JHR7 Insulin-degrading enzyme 2.98 Degradation of insulin, glucagon and other polypeptides
Q8VCW4 Protein unc-93 homolog B1 2.97 Innate immune response
O08599 Syntaxin-binding protein 1 2.87 Unknown
P38060 Hydroxymethylglutaryl-CoA lyase, mitochondrial 2.74 Unknown
Q11136 Xaa-Pro dipeptidase 2.73 Collagen catabolic process
Q8K4M5 COMM domain-containing protein 1 2.68 Promotes ubiquitination of NF-kappa-B subunit RELA
O55012 Phosphatidylinositol-binding clathrin assembly protein 2.53 Endocytosis
P49442 Inositol polyphosphate 1-phosphatase 2.36 DNA synthesis inhibition
Q8BYK6 YTH domain family protein 3 2.36 mRNA splicing
O35682 Myeloid-associated differentiation marker 2.34 Strongly up-regulated as multipotent progenitor cells
differentiate towards myeloid cells
Q4KML4 Costars family protein C6orf115 homolog 2.32 Unknown
Q61753 D-3-phosphoglycerate dehydrogenase 2.31 L-serine biosynthetic process
Q8VC28 Aldo-keto reductase family 1 member C13 2.31 Xenobiotic metabolic process
P97807 Fumarate hydratase, mitochondrial 2.28 Tricarboxylic acid cycle
Q8VBT0 Thioredoxin-related transmembrane protein 1 2.26 Cell redox homeostasis
Q3UX10 Tubulin alpha chain-like 3 2.26 Microtubule-based process
Q9JK38 Glucosamine 6-phosphate N-acetyltransferase 2.26 Glucosamine metabolic process
Q91V33 KH domain-containing, RNA-binding, signal transduction-
associated protein 1
2.26 G2/M transition of mitotic cell cycle; alternative splicing
All listed proteins were identified in 2 samples based on two or more peptides identified for every protein; classified according to the fold change in
expression based on global proteomic analysis. Selected functions of all listed proteins were assigned based on UniProtKB data base. ND- fold change in
protein expression was not computed since the indicated proteins were not detected in Puro-treated cells.
doi:10.1371/journal.pone.0133746.t001
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Table 2. Proteins not found or expressed at lower level in MCPIP1-expressing MSCs when compared with Puro-treated MSCs.





Selected function [Based on UniProtKB]
P08592 Amyloid beta A4 protein ND Notch signaling and α-ATPase activity inhibition; couples to
apoptosis-inducing pathways
Q9Z2G6 Protein sel-1 homolog 1 ND Notch signaling negative regulation; misfolded ER proteins
degradation
Q8C863 E3 ubiquitin-protein ligase Itchy ND Ubiquitinate CXCR4; Notch1 degradation controlling
Q4VSI4 Ubiquitin carboxyl-terminal hydrolase 7 ND p53-dependent cell growth repressor and apoptosis inducer
Q9D0S9 Histidine triad nucleotide-binding protein 2,
mitochondrial
ND Apoptotic sensitizer
Q9CRA5 Golgi phosphoprotein 3 ND Golgi membrane trafficking
Q3T1G7 Conserved oligomeric Golgi complex subunit 7 ND Golgi function
P70280 Vesicle-associated membrane protein 7 ND Transport vesicles targeting/ fusion
Q9ER41 Torsin-1B ND Secreted/membrane proteins folding
Q8JZK9 Hydroxymethylglutaryl-CoA synthase,
cytoplasmic
ND Fatty acid metabolism
Q6ZPR5 Sphingomyelin phosphodiesterase 4 ND Catalyzer of phosphorylcholine and ceramide formation
Q8VEE4 Replication protein A 70 kDa DNA-binding
subunit




Q61749 Translation initiation factor eIF-2B subunit
delta
ND Translation
Q8BG51 Mitochondrial Rho GTPase 1 ND Mitochondrial trafficking
P05622 Platelet-derived growth factor receptor beta ND Cell proliferation, survival, differentiation, chemotaxis and migration
Quantitatively less in MCPIP1-overexpressing MSCs when compared with Puro
Q80W54 CAAX prenyl protease 1 homolog -5.17 Farnesylated proteins proteolytic processing
O35783 Calumenin -5.09 Catalytic activity negative regulation
Q9JL26 Formin-like protein 1 -3.99 Cell morphology and cytoskeletal organization regulation
Q80TH2 Protein LAP2 -3.98 Nuclear envelope organisation
P53811 Phosphatidylinositol transfer protein beta
isoform
-2.55 Catalyzer of PtdIns and phosphatidylcholine between membranes
transfer
Q61655 ATP-dependent RNA helicase DDX19A -3.34 Apoptotic process positive regulation; mRNA transport
Q8CCJ3 E3 UFM1-protein ligase 1 -3.28 NF-kappaB transcription factor activity negative regulation
P68433 Histone H3.1 -3.02 Nucleosome assembly
P17742 Peptidyl-prolyl cis-trans isomerase A -2.89 Folding of proteins accelaration
Q6PGL7 WASH complex subunit FAM21 -2.78 Retrograde transport
O35864 COP9 signalosome complex subunit 5 -2.73 Unknown
P70452 Syntaxin-4 -2.65 Intracellular protein transport
P45878 Peptidyl-prolyl cis-trans isomerase FKBP2 -2.55 Peptidyl-proline modification
P84228 Histone H3.2 -2.49 Nucleosome assembly
Q9CQF9 Prenylcysteine oxidase -2.43 Prenylated proteins degradation
Q9D071 MMS19 nucleotide excision repair protein
homolog
-2.37 Unknown
Q91YP2 Neurolysin, mitochondrial -2.31 Oligopeptides such as neurotensin, bradykinin and dynorphin A
hydrolization
P15626 Glutathione S-transferase Mu 2 -2.31 Electrophilic compounds detoxification
Q9JIS8 Solute carrier family 12 member 4 -2.21 Potassium ion transport
(Continued)
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MCPIP1 enhances the angiogenic potential of MSCs following
stimulation accompanied by an increase in expression of proangiogenic
factors
After establishing that MCPIP1-MSCs at 72h after transduction exhibited greater proangio-
genic activity, we launched a long-term culture of these cells in proangiogenic medium (EGM-
2MV) and assessed the angiogenic differentiation after 5d and 10d of culture (Fig 3). The
expression of proangiogenic genes was investigated at mRNA level by real time RT-PCR and
we found elevated expression of Gata-2, vWF and VE-cadherin after 5 days of angiogenic dif-
ferentiation peaking at 10 days of culture in MCPIP1- MSCs when compared with Puro-treated
cells (Fig 3A). Enhanced angiogenic capacity of MCPIP1-MSCs was confirmed in a direct dif-
ferentiation assay followed by immunocytochemical staining for angiogenic proteins (Fig 3B
and 3C). Quantitative analyses revealed the greatest number of cells with endothelial pheno-
type expressing intranuclear transcription factor Gata-2 and membrane VE-cadherin within
MCPIP1-MSCs when compared with Puro cells (Fig 3C).
Moreover, MCPIP1-overexpressing MSCs exhibited greater angiogenic activity in the func-
tional Matrigel assay following pre-differentiation culture in proangiogenic medium (Fig 4).
Quantitative analysis of tube formation in vitro (S2 Fig) showed a greater number of capillaries
and branches within MSCs expressing MCPIP1 when compared with Puro-treated and
untreated Control MSCs after 5 and 10 days of endothelial pre-differentiation (Fig 4A and 4B
respectively; S2 Table).
To determine whether MCPIP1-overexpressing MSCs are able to secrete any protein
involved in angiogenesis that may stimulate neighboring cells in a paracrine manner, we com-
pared the secretome of MSCs overexpressing MCPIP1 and control MSCs by using Western
immunoblotting as well as quantitative analysis with the Luminex platform (Fig 5 and S3 Fig).
Based on our previous experimental data indicating that MCPIP1 up-regulates angiogenesis-
related genes and promotes capillary-like tube formation especially after 10 days following
endothelial stimulation, we used conditioned cell culture medium derived from
MCPIP1-MSCs and control MSCs at this time point. We found that secretion of endothelin, a
tissue inhibitor of metalloproteinase-1 (TIMP-1), Serpin E1, IFN-γ inducible- protein-10 (IP-
10), matrix metalloproteinase-3 (MMP-3), stromal cell-derived factor 1 (SDF-1), osteopontin
and insulin-like growth factor-binding protein 9 were significantly upregulated in MCPIP1-o-
verexpressing MSCs when compared with Puro cells (Fig 5). Next, we employed the quantita-
tive Luminex-based assay where we tested the secretion of selected proangiogenic proteins by
MCPIP1-overexpressing MSCs and controls at day 0, 5 and 10 following endothelial differenti-
ation (S3 Fig). We detected elevated concentration of endoglin in MCPIP1-overexpressing
MSCs when compared with Puro-treated cells, especially after 10 days of differentiation (S3
Table 2. (Continued)





Selected function [Based on UniProtKB]
Q9JIX8 Apoptotic chromatin condensation inducer in
the nucleus
-2.03 Apoptotic process positive regulation
All listed proteins were identified in 2 samples based on two or more peptides identified for every protein; classified in accordance with the fold change in
expression based on global proteomic analysis. Selected functions of the listed proteins were assigned based on UniProtKB data base. ND- fold change
in protein expression was not computed since the indicated proteins were not detected in MCPIP1-overexpressing cells.
doi:10.1371/journal.pone.0133746.t002
MCPIP1 Enhances Differentiation Potential of MSCs
PLOSONE | DOI:10.1371/journal.pone.0133746 July 27, 2015 12 / 25
Fig 3. Expression of angiogenesis- related markers in MSCs after angiogenic differentiation. (A) Expression of mRNA for Gata-2, vWF, Tie-2 and VE-
cadherin genes in MCPIP1- overexpressing MSCs after 5 and 10 days of angiogenic differentiation by real time RT-PCR. Fold change in mRNA
concentration in MCPIP1- transduced MSCs was computed when compared with Puro-treated cells (calculated as 1). (B) Representative images of
angiogenic marker expression assessed with immunocytochemistry in MCPIP1-overexpressing MSCs and Puro- treated MSCs differentiated into
endothelial phenotype in vitro. MCPIP1-overexpressing MSCs and Puro were stained against intranuclear transcription factor Gata-2 (Alexa Fluor 488,
green) and VE-cadherin (Alexa Fluor 546, red), whereas nuclei were co-stained with DAPI (blue). Cells were analyzed with Leica DM-IRE fluorescent
microscope. Scale bars indicate 50μm. (C)Quantitative analysis of angiogenic differentiation of MCPIP1- overexpressing MSCs and Puro cells after 5 and
10d of culture. Graphs represent percentages of cells expressing the indicated angiogenic marker identified by immunohistochemisty within both MSC
groups. All results are presented as means ± SD. Statistically significant differences (P<0.05) are shown when compared with Puro (*). Analysis based on
three independent experiments. Puro—empty vector-treated MSCs; MCPIP1- MSCs overexpressing MCPIP1.
doi:10.1371/journal.pone.0133746.g003
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Fig). Similar to previous results, the concentration of endothelin increased slightly after 5 and
10 days of pre-differentiation. Interestingly, in case of VEGF, we observed a decreased level of
this factor along the differentiation culture in all groups. In contrast, the concentration of SDF-
1 increased after 10 days of stimulation (Fig 5 and S3 Fig).
Importantly, with both assays, we did not detect any measurable level of IL-1β or other
inflammatory cytokines or chemokines produced by MCPIP1-overexpressing MSCs (data not
shown). These data confirm the anti-inflammatory properties of MCPIP1 also in MSCs that
have already been reported for other cell types [21, 23]. Finally, we detected decreased concen-
tration of MCP-1 released by MCPIP1-overexpressing MSCs when compared with Puro-
treated and untreated MSCs that remained consistent during differentiation culture (S3 Fig).
This may suggest a negative feedback loop of MCP-1 regulation by MCPIP1 in MSCs.
Fig 4. Functional angiogenic potential of MSCs following predifferentiation into endothelial cells by capillary-like formation assay. (A)Graphs
represent quantitative assessment of branches (left graphs) and capillaries (right graphs) formed by MSCs differentiated in proangiogenic medium for 5 days.
(B)Graphs show quantitative assessment of branches (left graphs) and capillaries (right graphs) formed by MSCs differentiated in proangiogenic medium for
10 days. HUVEC cells were used as positive control, while freshly isolated BM cells represent the negative control. Six randomly selected high-power field
images were selected for quantification. Numbers of branches and capillaries formed by each cell fraction were computed based on microscopic images as
shown in S2 Fig and the detailed results are presented in S2 Table. All results are presented as mean ± SD. Statistically significant differences (P<0.05) are
shown when compared with Puro (*) and Control (#). Analysis based on three independent experiments. Control—untreated MSCs; Puro—empty vector-
treated MSCs; MCPIP1- MSCs overexpressing MCPIP1.
doi:10.1371/journal.pone.0133746.g004
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MCPIP1 promotes cardiomyogenic differentiation of MSCs
To establish the impact of MCPIP1 on cardiac differentiation, MCPIP1-MSCs and control cells
were differentiated into cardiomyocytes in vitro as previously described [32]. We analyzed
mRNA expression for cardiac markers such as Gata-4, Nkx2.5, Myl-2 and Myh-6 after 5 and
10 days of differentiation induction (Fig 6A). We found that the expression of these genes was
markedly elevated after 5 and 10 days of cardiomyogenic differentiation induction in MCPI-
P1-overexpressing MSCs when compared with Puro-treated cells (Fig 6A).
Enhanced cardiomyogenic capacity of MSCs overexpressing MCPIP1 was confirmed by
immunocytochemical staining for typical cardiac proteins following differentiation in cardiac
medium in vitro (Fig 6B and 6C). Quantitative assessment of differentiating MSCs (after 5 and
10 days of culture) revealed greater numbers of cells with cardiac phenotype expressing intra-
nuclear cardiac transcription factor Gata-4 and cytoplasmic structural protein troponin T-C
Fig 5. Semiquantitative analysis of angiogenesis-related proteins secreted by MSCs after 10 days of endothelial culture byWestern blotting. (A)
Representative nitrocellulose membranes incubated with conditioned culture medium harvested from cultures of all three experimental groups of MSC
(MCPIP1-overexpressing MSCs, empty vector- treated (Puro) MSCs and untreated (Control) MSCs). Pairs of duplicate spots represent each angiogenesis-
related protein. Pair of duplicate spots with upregulated expression when compared with control cells were included in brackets. (B) Semiquantitative
assessment of selected protein concentrations based on pixel density analysis with Quantity One software. All results are presented as means ± SD.
Statistically significant differences (P<0.05) are shown when compared with Puro (*) and Control (#). The analysis was conducted using a mixture of
conditioned media collected under cells prepared from three independent experiments. Control—untreated MSCs; Puro—empty vector-treated MSCs;
MCPIP1- MSCs overexpressing MCPIP1.
doi:10.1371/journal.pone.0133746.g005
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Fig 6. Expression of cardiac markers in MSCs after cardiomyogenic differentiation. (A) Expression of mRNA for Nkx2.5, Gata-4, Myl-2 and Myh-6
genes after 5 and 10 days of cardiac differentiation by real time RT-PCR. Fold change in mRNA concentration in MCPIP1- transduced MSCs was computed
when compared with Puro-treated cells (calculated as 1). (B) Representative images of cardiac markers expression assessed with immunocytochemistry in
MCPIP1-overexpressing MSCs and Puro- treated MSCs differentiated into cardiac phenotype in vitro. MCPIP1-overexpressing MSCs and Puro were stained
against intranuclear transcription factor Gata-4 (Alexa Fluor 488, green) and Troponin T-C (Alexa Fluor 546, red), whereas nuclei were co-stained with DAPI
(blue). Cells were analyzed with a Leica DM-IRE fluorescent microscope. Scale bars indicate 50μm. (C)Quantitative analysis of cardiomyogenic
differentiation of MCPIP1-overexpressing MSCs and Puro cells after 5 and 10d of culture. Graphs represent percentages of cells expressing the indicated
cardiac marker identified by immunocytochemisty within both MSC groups. All results are presented as means ± SD. Statistically significant differences
(P<0.05) are shown when compared with Puro (*). Analysis based on three independent experiments. Puro—empty vector-treated MSCs; MCPIP1- MSCs
overexpressing MCPIP1.
doi:10.1371/journal.pone.0133746.g006
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within MCPIP1-MSCs when compared with Puro cells (Fig 6C). Interestingly, we found
increase in expression of autophagy related genes in MCPIP1-MSCs undergoing cardiac or
angiogenic differentiation (Fig 7A and 7B).
Our findings indicate that MCPIP1 protein enhances not only angiogenic, but also cardio-
myogenic differentiation of MSCs. Interestingly, our gene expression and proteomic studies
suggest that such processes may be accompanied with intracellular reorganization via autop-
hagy, which may represent new interesting subject for future studies and needs to be further
investigated (Fig 7C).
Discussion
According to annual reports of the World Health Organization, ischemic heart disease (IHD)
is one of the leading causes of death worldwide [33]. IHD may lead to acute ischemic events
such as myocardial infarction (MI) resulting in massive cardiomyocyte death due to apoptosis
and necrosis [34]. The profound inflammatory reaction that follows ischemia contributes pro-
gression of ventricular remodeling and eventually dysfunction, heart failure and higher mortal-
ity [35]. Therapeutic approaches have therefore been aimed at inhibiting the adverse
consequences of myocyte loss and tissue remodeling. These have included both pharmacologi-
cal methods and cell-based regenerative strategies with stem cells [36–38].
Bone marrow MSCs, a subset of adherent cells with multipotent differentiation capacity, are
able to differentiate into several cell types, including cardiomyocytes and endothelial cells [39,
40]. Due to this broad differentiation potential, low immunogenicity, and anti-inflammatory
activities, MSCs have been widely employed for myocardial salvage, repair, and regeneration
following ischemic injury [41–44].
In this study, BM-derived MSCs were genetically modified to overexpress MCPIP1, a pro-
tein exhibiting a strong silencing potential of the inflammatory response and modulation of
gene expression by RNase activity [21, 23, 24]. MCPIP1 has also recently been implicated in
adipogenesis [28] and angiogenesis [25]. Although, a role of MCPIP1 in cardiomyocyte sur-
vival was reported [26, 45], the role of this protein in cardiomyogenesis from stem cells has
never been examined.
In view of the role of MCPIP1 in cell survival and initiation of apoptosis [25, 46, 47], we
evaluated the activation of proapoptotic caspase-3 and -7 as well as the extent of cells undergo-
ing apoptosis and necrosis. By employing several independent assays, we showed that MCPIP1
overexpression did not negatively impact the viability of MSCs. Moreover, we observed normal
metabolic activity based on measurement of total ATP concentration in such cells. These
results indicate greater resistance of stem cells such as BM-derived MSCs against activation of
apoptosis via MCPIP1 when compared with other more mature cells such as primary HUVECs
and cardiomyocytes previously examined by other groups [25, 46, 47].
Interestingly, other studies have reported a beneficial effect of cardiac MCPIP1 expression
on myocardial injury. Using a transgenic mouse model with myocardial MCPIP1 expression
(under α-MHC promoter), Niu et al. reported significant attenuation of inflammation-related
cardiac dysfunction [26, 45]. The authors observed decreased expression of inflammatory cyto-
kines and iNOS as well as caspase 3/7 activity and apoptosis in MCPIP1-expressing myocytes
following treatment with LPS when compared with wild type animals [26, 45]. These results
were confirmed by other investigators reporting lower levels of inflammatory cytokines (e.g.
TNF-α, IL-1β) along with higher levels of anti-inflammatory cytokines (e.g. IL-10) in myocar-
dium of animals with MCPIP1 expression following LPS treatment [48–50]. This phenomenon
may be related to RNase activity of MCPIP1 due to the presence of the PilT N-terminus
domain which has been shown to promote degradation of mRNA for inflammatory cytokines
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Fig 7. Expression of autophagy- related genes in MSCs during differentiation. Expression of mRNA for Beclin-2 and Atg7 in MCPIP1- overexpressing
MSCs after 5 and 10 days of cardiomyogenic (A) and angiogenic (B) differentiation by real time RT-PCR. Fold change in mRNA concentration in MCPIP1-
transduced MSCs was computed when compared with Puro-treated cells (calculated as 1). All results are presented as means ± SD. Statistically significant
differences (P<0.05) are shown when compared with Puro (*). Analysis based on three independent experiments. (C) Potential functional network impacted
by MCPIP1 in MSC cells. MCPIP1 increases angiogenic and cardiac differentiation capacity of MSCs which is accompanied with decrease in expression of
early stem cell-related genes and proliferation rate as well as with increase in expression of tissue commitment- related genes and several proteins involved
in the differentiation processes. Moreover, the increase in differentiation activity of MSCs may be accompanied with intracellular reorganization involving
process of autophagy.
doi:10.1371/journal.pone.0133746.g007
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such as IL-6 and IL-1 as well as select pre-miRNAs that regulate other factors involved in
inflammation [21, 23, 24]. Moreover, Morimoto et al. have demonstrated a cardioprotective
effect of MCP-1 (acting via stimulation of MCPIP1 expression) on myocardium following
ischemia/ reperfusion (I/R) injury in mice [51, 52]. Thus, the findings suggest that MSCs over-
expressing MCPIP1 may have an anti-apoptotic and anti-inflammatory role on myocardium
following transplantation into ischemic heart tissue.
Moreover, MCPIP1 may also be involved in deubiquitination of TRAF family proteins
which are known to mediate inflammatory response [53]. Interestingly, our proteomic analysis
of MSCs from all three experimental groups revealed expression of ubiquitin-conjugating
enzyme E2 H involved in protein ubiquitination and ubiquitin fusion degradation protein 1
responsible for proteasome-mediated protein catabolic process in MCPIP1-overexpressing
MSCs, but not in control MSCs. Thus, these data suggest that MCPIP1 expressed in MSCs may
indirectly enhance ubiquitination of selected proteins resulting in their degradation. This phe-
nomenon may also potentially be involved in inhibition of inflammatory cytokine production
by MCPIP1-MSCs; however, this needs to be further evaluated. Overall, these data again indi-
cate that MCPIP-1 may exert anti-inflammatory and anti-apoptotic properties in MSCs.
Interestingly, we found that although MCPIP1 did not notably affect morphology or anti-
genic phenotype of MSCs, it significantly impaired proliferation of MSCs expressing MCPIP1
when compared with Puro vector-treated cells. Consistently, global proteomic analysis revealed
that MCPIP1-MSCs expressed greater levels of several proteins involved in negative regulation
of cell proliferation and cell cycle arrest, including testin and protein phosphatase 1G. It is gen-
erally known that a decrease in cell proliferation may often be accompanied by induction of
cell differentiation [54, 55]. Thus, we expected that the effect of MCPIP1 on MSC proliferation
may be related to greater differentiation status of these cells confirmed by further experiments.
It has been reported that MCPIP1 may enhance the angiogenic potential of HUVEC cells,
which represent mature cells, and BM-derived monocytic cells [25, 56]. Using Matrigel assay,
Niu and colleagues have shown that HUVECs stimulated with MCP-1 show greater angiogenic
potential. Importantly, knockdown of MCPIP1 in HUVECs resulted in suppression of VEGF
and hypoxia-inducible factor-1α (HIF-1α) genes, the angiogenesis- related factors induced by
MCP-1 [25]. Similarly, angiogenic differentiation of human BM-derived monocytic cells
(BMNCs) with MCPIP1 expression and enhanced neovascularization after transplantation
into ischemic tissues in vivo has also been reported [56]. However, the impact of MCPIP1 on
the angiogenic capacity of stem cells such as MSCs has never been studied.
Our results show, for the first time, that MCPIP1 may enhance angiogenic differentiation of
adult stem cells such as MSCs in vitro. Our results also reveal significant upregulation of endo-
thelial transcription factors and structural proteins, including Gata-2 and VE-cadherin at both
mRNA and protein levels in MSCs expressing MCPIP1 following culture in proangiogenic
medium. Moreover, these data also establish that MCPIP1 enhances formation of capillary-like
structures in Matrigel assay after proangiogenic stimulation. Interestingly, the greater angio-
genic capacity of MCPIP1-MSCs was accompanied by decreased expression of early stem cell-
related genes such as Oct-4, Nanog and Sox2. Our data indicate enhanced angiogenic capacity
of MSCs expressing MCPIP1 when compared with control cells confirming proangiogenic
activity of MCPIP1 not only in mature cells but also in stem cells.
In the present study we also report, for the first time, that MCPIP1 expression enhances dif-
ferentiation of BM-derived MSCs into cardiomyocytes in vitro. We found that MCPIP1 pro-
moted the acquisition of a cardiac phenotype by MSCs, evidenced by upregulation of
cardiomyogenesis-related transcription factors, such as Gata-4 and Nkx2.5, as well as structural
proteins, including Myh-6 and Myl-2. Furthermore, we detected a greater number of cells
expressing Gata-4 and troponin T-C at the protein level in MCPIP1-MSCs following 10 days
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of culture in cardiomyogenic medium. Our findings therefore support a role of MCPIP1 in
generation of cardiomyocytes stem cells. These data also provide the rationale to develop novel
strategies to transplant MSCs overexpressing MCPIP-1 into ischemic myocardium to enhance
cardiac and vascular regeneration.
Current evidence from in vitro and in vivo studies strongly indicate that major mechanisms
of stem cell-mediated neovascularization include not only effective stem cell retention and vas-
cular differentiation in the infarcted heart, but also secretion of several factors impacting endog-
enous cells in a paracrine manner [57, 58]. Interestingly, we found that MCPIP1-overexpressing
MSCs secrete higher levels of several proteins involved in angiogenesis including endoglin,
endothelin, TIMP-1, serpin E1, IP-10 andMMP-3, when compared with controls. Furthermore,
we observed a higher level of chemokine SDF-1 secreted by MSCs expressing MCPIP1 when
compared with control cells. SDF-1 has been shown to play a pivotal role in directing CXCR4
+ stem cells toward the site of injury, an essential step for cardiac repair [59–61]. Our data sug-
gest that production of SDF-1 by transplanted MCPIP1-MSCs may enhance homing of other
endogenous stem cells to the infarcted heart and promote regeneration. Aside from serving as a
homing factor, SDF-1 has also been shown to be a proangiogenic factor [62, 63], and as such
may increase new vessel formation when released by transplanted MCPIP1-MSCs.
Interestingly, it has been recently demonstrated that forced expression of MCPIP1 may
induce autophagy in HUVECs finally leading to improvement of angiogenic potential [64].
The phenomenon may be explained by the necessary rebuilding of cell contents during differ-
entiation via elimination of several proteins and organelles associated with metabolic changes
[65–67]. Our global proteomic analysis showed increased expression of autophagy regulators,
such as CDGSH iron-sulfur domain-containing protein 2 exclusively in MSCs expressing
MCPIP1. Importantly, the expression of genes related to autophagy such as beclin 2 and Atg7
was greatly increased in MCPIP1-MSCs during their angiogenic and cardiac differentiation.
Moreover, we found several proteins potentially involved in the intracellular cytoskeleton and
membrane reorganization to be expressed at a higher level in MCPIP1-MSCs, including Ras-
related protein Rab-11B, tubulin alpha chain-like 3 or SLAIN motif-containing protein
involved in microtubule organization. Elevated expression of proteins involved in intracellular
membrane trafficking and recruiting effector molecules critical for vesicle traffic along actin-
or microtubule-based cytoskeletal structures, such as secretory carrier-associated proteins or
Rab proteins was also reported [68]. The data may indicate that MSCs expressing MCPIP1
contain a set of molecules participating in intracellular component remodeling and vesicular
transport facilitating differentiation processes in these SCs. Thus, the observed greater angio-
genic and cardiac differentiation potential of MCPIP1-MSCs may be preceded by autophagy
related to MCPIP1 expression and intracellular reorganization. However, this interesting phe-
nomenon warrants further investigation.
In summary, overexpression of MCPIP1 reduces the expression of pluripotency associated
markers, and increases angiogenic and cardiomyogenic potential of MSCs. MCPIP1 does not
notably impact MSC viability, metabolic activity, morphology, and antigenic profile, yet
reduced the proliferation rate. MCPIP1-overexpressing MSCs express several proteins poten-
tially involved in angiogenesis, autophagy and processes accompanying cell differentiation (Fig
7C). These results strongly indicate the beneficial impact of MCPIP1 protein on MSC features
which may be utilized for potential clinical applications.
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S1 Fig. Transduction efficiency and MCPIP1 overexpression in murine BM- derived MSCs
at 72h post transduction.Morphology of the entire population of BM- derived MSCs follow-
ing transduction with a vector carrying GFP by fluorescence (FL) microscopy. BF—Brightfield
image, green FL—GFP- expressing MSCs, combo—combined image. Scale bars: 100 μm. (B)
Representative histograms visualizing average values of transduction efficiency with pMX-
based retroviral vector carrying GFP in the whole MSC population when compared with non-
transduced Control MSCs. (C) Quantitative analysis of mRNA concentration for MCPIP1 at
48h and 72h following retroviral transduction. Black bars represent MSCs transduced with vec-
tor carrying MCPIP1 sequence, while hatched and white bars show MSCs transduced with
empty vector (Puro) or untreated (Control) MSCs, respectively. The expression of MCPIP1 in
Puro-treated cells is set as 1. (D) MCPIP1 overexpression in murine BM- derived MSCs. Upper
panel: Representative Western blotting analysis of MCPIP1 protein expression at 48 and 72h
following transduction. Actin was used as endogenous control. Lower panel: Semiquantitative
assessment of MCPIP1 protein and actin concentrations based on pixel density analysis with
Quantity One software. (E) Viability of MCPIP1-overexpressing MSCs when compared with
Puro-treated cells (set as 1) at 48 and 72h following transduction by MTT assay. (F) Metabolic
activity of MCPIP1-overexpressing MSCs when compared with Puro-treated cells (set as 1)
assessed by ATP concentration measurement. All results are presented as mean ± SD. Statisti-
cally significant differences (P<0.05) are shown in comparison with Puro () and untreated
Control (#) cells. Analysis based on three independent experiments. Control—untreated
MSCs; Puro—empty vector-treated MSCs; MCPIP1- MSCs overexpressing MCPIP1.
(TIF)
S2 Fig. Strategy for semi-quantitative analysis of angiogenic potential determined by capil-
lary-like formation assay. Six representative brightfield images of high-power fields (objective
magnification 4x) were randomly selected and taken at every experimental timepoint for quan-
titative assessment. (A) Total number of capillaries were counted as shown by circles. (B) Total
number of branches were assessed as shown by crosses. Average mean and SD were computed
for every experimental timepoint. Control—untreated MSCs; Puro—empty vector-treated
MSCs; MCPIP1- MSCs overexpressing MCPIP1.
(TIF)
S3 Fig. Quantitative analysis of angiogenesis-related proteins secreted by MSCs after 5 and
10 days of proangiogenic stimulation. Concentration of analytes was evaluated in cell culture
supernatants harvested from cultures of all three experimental groups of MSC (MCPIP1-over-
expressing MSCs, empty vector- treated (Puro) MSCs and untreated (Control) MSCs) with
Luminex xMAP technology using Mouse Angiogenesis/ Growth Factor Magnetic Bead Panel.
Control—untreated MSCs; Puro—empty vector-treated MSCs; MCPIP1- MSCs overexpres-
sing MCPIP1.
(TIF)
S1 Table. Quantitative analysis of number of branches and capillaries formed by MSCs in
capillary-like formation assay—number of branches and capillaries calculated per field
formed by non-differentiated MSC groups (at 72h following transduction).
(DOC)
S2 Table. Quantitative analysis of number of branches and capillaries formed by MSCs in
capillary-like formation assay—number of branches and capillaries formed by MSC groups
after 5 and 10 days of endothelial stimulation.
(DOC)
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